Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Teva
UBS
Mallinckrodt
US Department of Justice
Johnson and Johnson
AstraZeneca
Fuji
Chubb
Baxter

Generated: January 18, 2018

DrugPatentWatch Database Preview

ERAXIS Drug Profile

« Back to Dashboard

When do Eraxis patents expire, and when can generic versions of Eraxis launch?

Eraxis is a drug marketed by Vicuron and is included in one NDA. There are three patents protecting this drug.

This drug has sixty-seven patent family members in twenty-nine countries.

The generic ingredient in ERAXIS is anidulafungin. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the anidulafungin profile page.
Summary for ERAXIS
International Patents:67
US Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 26
Clinical Trials: 11
Patent Applications: 1,102
Drug Prices:see details
DailyMed Link:ERAXIS at DailyMed
Drug patent expirations by year for ERAXIS
Pharmacology for ERAXIS
Ingredient-typeLipopeptides
Drug ClassEchinocandin Antifungal

US Patents and Regulatory Information for ERAXIS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vicuron ERAXIS anidulafungin INJECTABLE;IV (INFUSION) 021632-001 Feb 17, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Vicuron ERAXIS anidulafungin INJECTABLE;IV (INFUSION) 021632-002 Nov 14, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Vicuron ERAXIS anidulafungin INJECTABLE;IV (INFUSION) 021632-001 Feb 17, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Vicuron ERAXIS anidulafungin INJECTABLE;IV (INFUSION) 021632-001 Feb 17, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Vicuron ERAXIS anidulafungin INJECTABLE;IV (INFUSION) 021632-002 Nov 14, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Vicuron ERAXIS anidulafungin INJECTABLE;IV (INFUSION) 021632-002 Nov 14, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for ERAXIS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Vicuron ERAXIS anidulafungin INJECTABLE;IV (INFUSION) 021632-001 Feb 17, 2006 ➤ Subscribe ➤ Subscribe
Vicuron ERAXIS anidulafungin INJECTABLE;IV (INFUSION) 021632-002 Nov 14, 2006 ➤ Subscribe ➤ Subscribe
Vicuron ERAXIS anidulafungin INJECTABLE;IV (INFUSION) 021632-001 Feb 17, 2006 ➤ Subscribe ➤ Subscribe
Vicuron ERAXIS anidulafungin INJECTABLE;IV (INFUSION) 021632-002 Nov 14, 2006 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for ERAXIS

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,790,744 Cyclic peptide antifungal agents and process for preparation thereof ➤ Subscribe
5,932,543 Cyclic peptide antifungal agents and process for preparation thereof ➤ Subscribe
6,384,013 Cyclic peptide antifungal agents and process for preparation thereof ➤ Subscribe
6,916,784 Cyclic peptide antifungal agents and process for preparation thereof ➤ Subscribe
6,743,777 Cyclic peptide antifungal agents and process for preparation thereof ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for ERAXIS

Supplementary Protection Certificates for ERAXIS

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0334 Netherlands ➤ Subscribe 300334, 20130318, EXPIRES: 20180317
C002/2008 Ireland ➤ Subscribe SPC002/2008: 20081105, EXPIRES: 20180317
406 Luxembourg ➤ Subscribe 91406, EXPIRES: 20180318
00334 Netherlands ➤ Subscribe PRODUCT NAME: ANIDULAFUNGIN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/07/416/001 20070920
0561639/01 Switzerland ➤ Subscribe PRODUCT NAME: ANIDULAFUNGIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 58325 03.09.2009
2008 00017 Denmark ➤ Subscribe
C/GB08/016 United Kingdom ➤ Subscribe PRODUCT NAME: ANIDULAFUNGIN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/416/001 20070920
C0009 France ➤ Subscribe PRODUCT NAME: ANIDULAFUNGINE; REGISTRATION NO/DATE: EU/1/07/416/001 20070920
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Queensland Health
Baxter
Express Scripts
Moodys
McKinsey
Fish and Richardson
US Department of Justice
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot